—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Illumina Inc (ILMN) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ILMN, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-09-25

DayWeekMonth3 months
ILMN−1.4%+12.7%+20.1%+52.9%
Longevity & Healthspan−0.3%+4.5%+0.5%—
HALO Growth 1000.0%+0.2%−7.6%—

Against the index: 12.5 pts ahead on the week, 27.7 pts ahead on the month; against its Longevity & Healthspan sleeve 19.6 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sector × region Health care in US: +1.8% week · −1.3% month · +6.9% quarter · +12.8% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-26
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.65 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How ILMN has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.65 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Illumina Inc moved 0.65% on average · correlation 0.12 · higher than 66% of US names
  • Beta, last 3 months 0.69 about the same as over the year
  • On the 10 worst bond days +0.55% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +7.25% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against ILMN on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Illumina Inc

ILMN in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Illumina builds the sequencing and array instruments, and the reagents and flow cells that run through them, used to read DNA and RNA. It sells whole-genome, exome and targeted sequencing kits and services to research centres, hospitals, government labs and biotech and diagnostics companies, mostly through direct sales and distributors. It also runs partnerships on oncology sequencing and on the data pipelines that turn raw reads into usable results. Illumina is based in San Diego.
Where it sits in the stack
Illumina carries no seat in Rubin, our AI build-out index; it sits in the HALO Growth 100, our growth index outside the megacaps, in the Longevity & Healthspan sleeve. That sleeve groups diagnostics-at-scale and gene-editing platforms whose demand follows demographics, and Illumina supplies the sequencing hardware those platforms are built on.
Who it is priced against
The diary's peer group for this sleeve pairs GLP-1 leaders and gene-editing platforms with diagnostics-at-scale names and biopharma compounders, including Eli Lilly, Regeneron, Vertex, Novo Nordisk, Amgen and Natera; the market also names Thermo Fisher Scientific as a direct competitor in sequencing.
Why Closelooknet tracks it
Illumina holds a seat in the HALO Growth 100 and carries a Closelooknet score, with momentum reading strongest and valuation weakest across the score's modules; the diary has not yet quoted it in an edition.
What the diary watches
Whether momentum keeps running ahead of valuation, or whether the gap narrows as analyst targets and the score's modules move against each other.

Illumina Inc (ILMN) trades on US exchanges, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 55/100 composite (momentum 96, quality 76, valuation 22) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Argus, 2026-09-03

The Street on this name

Analyst actions and the latest print for ILMN from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Argus — target 235 from 180 Target raised to $235 from $180 (+10.2% to spot) 2026-09-03

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 742 m USD in FY2025

Dividends and capital return

What ILMN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months No cash distribution in the last twelve months earlier distributions show in the price series, see the years below
  • Last distribution 3.00 USD per share as the price series records it, within days of the ex-date 2024-06-25
  • By calendar year 2024: 3.00 USD (partial) first distribution recorded in the three-year window: 2024-06-25
  • Buybacks, FY2025 742 m USD 1.9% of today's market value
  • Share count −1.9% in FY2025 275 m USD of stock-based compensation in the year
  • Capital returned 742 m USD · 80% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Illumina Inc (ILMN)?

Illumina Inc trades as ILMN on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is ILMN in a Closelooknet index?

Yes — Illumina Inc is a constituent of HALO Growth 100, as of 2026-09-26.

What is Illumina Inc's Closelooknet composite score?

55 out of 100, with momentum 96, quality 76 and valuation 22 sub-scores, as of 2026-09-26. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ILMN trade against its moving averages?

Up 7.3% at the close: Above both trend lines; one of the day's strongest moves. As of 2026-09-24 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is ILMN doing against its Closelooknet index?

Over the past month Illumina Inc is +20.1% against −7.6% for the HALO Growth 100 — 27.7 points ahead of its index, as of 2026-09-25. Its Longevity & Healthspan sleeve is +0.5% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Illumina Inc trade when bond yields rise?

Over the past year Illumina Inc had a beta of 0.65 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 66% of US names. On the 10 sessions in which long bonds fell most it moved +0.55% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Illumina Inc do?

Illumina builds the sequencing and array instruments, and the reagents and flow cells that run through them, used to read DNA and RNA. It sells whole-genome, exome and targeted sequencing kits and services to research centres, hospitals, government labs and biotech and diagnostics companies, mostly through direct sales and distributors. It also runs partnerships on oncology sequencing and on the data pipelines that turn raw reads into usable results. The diary's peer group for this sleeve pairs GLP-1 leaders and gene-editing platforms with diagnostics-at-scale names and biopharma compounders, including Eli Lilly, Regeneron, Vertex, Novo Nordisk, Amgen and Natera; the market also names Thermo Fisher Scientific as a direct competitor in sequencing.

Where does Illumina Inc sit in the AI build-out?

Illumina carries no seat in Rubin, our AI build-out index; it sits in the HALO Growth 100, our growth index outside the megacaps, in the Longevity & Healthspan sleeve. That sleeve groups diagnostics-at-scale and gene-editing platforms whose demand follows demographics, and Illumina supplies the sequencing hardware those platforms are built on. Illumina holds a seat in the HALO Growth 100 and carries a Closelooknet score, with momentum reading strongest and valuation weakest across the score's modules; the diary has not yet quoted it in an edition.

Does Illumina Inc pay a dividend?

No cash distribution shows in Illumina Inc’s price series over the last twelve months. In fiscal 2025 the company bought back 742 m USD of its own shares, 80% of that year’s free cash flow. The share count fell 1.9% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Illumina Inc recently?

The most recent analyst action on Illumina Inc on the Closelooknet wire is a price target by Argus on 2026-09-03 (target 235 from 180). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ILMN, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.